Ligne de temps

Nicolas Escriou
Chercheur(euse) Permanent(e)
02 avr. 2024
publication

A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: candidate selection in a preclinical murine model.

Lire plus
01 avr. 2023
publication

Development and comparative evaluation of SARS-CoV-2 S-RBD and N based ELISA tests in various African endemic settings

Lire plus
01 janv. 2022
publication

Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study.

Lire plus
21 mai 2021
publication

Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.

Lire plus
01 janv. 2021
publication

High seroprevalence but short-lived immune response to SARS-CoV-2 infection in Paris.

Lire plus
16 déc. 2020
publication

Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models.

Lire plus
02 sept. 2020
publication

A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations

Lire plus
10 avr. 2020
project

CORONABODIES

Lire plus
04 juil. 2015
project

Bivalent vaccines derived from measles vaccine

Lire plus